Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma
Condition: PD-1 Refractory Advanced Melanoma Interventions: Biological: Responder-Derived Fecal microbiota transplantation (R-FMT; Drug: Pembrolizumab; Drug: Lenvatinib Sponsors: Diwakar Davar; Merck Sharp & Dohme LLC; Gateway for Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials